While in hematologic tumors, including chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), and DLBCL, it is generally acknowledged that IL-9 promotes tumor progression through the T-lymphocyte growth factor (50–52). This evidence concerns the gene IL9 and Hodgkins lymphoma.